June 23, 2016 07:00 AM EDT
Pharma

Zom­bie biotech Eleven Bio sheds staff in the fi­nal wind down

John Carroll

Editor & Founder

Ham­mered by back-to-back piv­otal tri­al fail­ures, Eleven Bio­ther­a­peu­tics ($EBIO) is con­tin­u­ing to wind down its op­er­a­tions. The biotech not­ed that it whacked 14 staffers last …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times